Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 8/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603979 | 0.87 | ALPL (0.43) | MAP4K2EGLN2DPP4ALPLALPG | |
| SCHEMBL10269994 | 0.86 | IDO1 (0.41) | MAP4K2MAPTCNR1 | |
| SCHEMBL3608864 | 0.85 | EGLN2 (0.41) | MAP4K2EGLN2DPP4ALPLALPG | |
| SCHEMBL10270149 | 0.85 | DPP4 (0.43) | MAP4K2EGLN2DPP4NPC1GSK3B | |
| Trifluoroacetic Acid SCHEMBL3605360 | 0.84 | DPP4 (0.38) | MAP4K2EGLN2DPP4ALPLALPG | |
| SCHEMBL4554539 | 0.84 | MAP4K2 (0.38) | MAP4K2EGLN2DPP4ALPLALPG | |
| SCHEMBL3608230 | 0.82 | MAP4K2 (0.38) | MAP4K2DPP4ALPLGSK3BMAPT | |
| SCHEMBL3613066 | 0.82 | GSK3B (0.40) | MAP4K2EGLN2DPP4ALPLALPG | |
| SCHEMBL3603724 | 0.82 | ALPL (0.41) | MAP4K2EGLN2DPP4ALPLNPC1 | |
| SCHEMBL3617050 | 0.82 | LMNA (0.39) | EGLN2DPP4ALPLALPGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | MAP4K2 1001/4885EGLN2 1710/4885DPP4 436/4885 |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | THPO, TYMP, TPMT | MAP4K2 605/4885EGLN2 2683/4885DPP4 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.